(Q44552628)

4 December 2017

title

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial (English)

1 reference

obsessive-compulsive disorder

4 December 2017

main subject

1 reference

Ozmen Metin

1

1 reference

4 December 2017

Kemal Yazici

series ordinal

2

1 reference

4 December 2017

Senel Tot

series ordinal

3

1 reference

4 December 2017

Aylin Ertekin Yazici

series ordinal

4

1 reference

4 December 2017

publication date

1 August 2003

1 reference

4 December 2017

published in

Human Psychopharmacology

1 reference

4 December 2017

volume

18

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

463-467

1 reference

Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action

4 December 2017

cites work

1 reference

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

21 January 2018

1 reference

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

21 January 2018

1 reference

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography

21 January 2018

1 reference

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder

21 January 2018

1 reference

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

21 January 2018

1 reference

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

21 January 2018

1 reference

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

21 January 2018

1 reference

7 January 2021

A comparative review of new antipsychotics

1 reference

7 January 2021

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

1 reference

7 January 2021

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study

1 reference

7 January 2021

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

7 January 2021

Can clozapine trigger OCD?

1 reference

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

7 January 2021

Neurobiology and clinical pharmacology of obsessive-compulsive disorder

1 reference

7 January 2021

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

7 January 2021

Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex

1 reference

7 January 2021

Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study

1 reference

7 January 2021

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

1 reference

7 January 2021

Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs

1 reference

7 January 2021

Risperidone and obsessive-compulsive symptoms

1 reference

7 January 2021

Evaluation of the reported association of obsessive-compulsive symptoms or disorder with Tourette's disorder

1 reference

7 January 2021

Yale-Brown Obsessive Compulsive Scale and US National Institute of Mental Health Global Obsessive Compulsive Scale in Turkish: reliability and validity.

1 reference

7 January 2021

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.512

1 reference

4 December 2017

1 reference